During this study, BalB/C mice were used as recipients and C57 bl/6 mice as donors. Recipients were given 800 cGys of total body irradiation (TBI) on day 0. Transplantation was carried out as follows: group (1): TBI on day 0; group (2): TBI on day 0 and transplantation on day þ 1; group (3): TBI on day 0 and transplantation on day 4; group (4): TBI on day 0 and transplantation started from day 4 through day 8. Mice that received TBI only died by day 11. All group 2 mice developed aGVHD and died by day þ 15. In total, 70% of group 3 were still surviving by day 60 (Po0.001, compared to day þ 1 transplantation). Survival rates were 90% at day 60 for group 4 (Po0.001 compared to day 1 transplantation). No survival advantage was found between animals transplanted on day 4 and animals with delayed sequential transplantation (P ¼ 0.1). Significant engraftment was found in both groups 3 and 4, with no significant differences in the percentages of donor-derived cells between the two groups (P40.05). These data demonstrate that either delayed or delayed sequential transplantation after TBI can be an effective approach for aGVHD prevention.
Acute graft-versus-host disease (aGVHD) remains the major complication of allogeneic bone marrow transplantation, and it has been the primary limitation for its wider application. The pathophysiology of GVHD is complex, with numerous variables affecting its incidence and severity. 1, 2 The earliest phase of acute GVHD starts before donor cells are infused. The transplant conditioning regimen is an important variable in the pathogenesis of acute GVHD because it can damage and activate host tissues. Activated host cells secrete inflammatory cytokines. [3] [4] [5] Such inflammatory cytokines may upregulate adhesion molecules 6 and major histocompatibility complex antigens (MHC), 7, 8 thereby enhancing the recognition of host MHC or minor histo-compatibility antigens by mature donor T cells after the graft is infused. This scenario is in accordance with the observation that an enhanced risk of GVHD is associated with intensive conditioning regimes. A direct link exists between inflammatory reactions induced by irradiation and cytotoxic treatment and occurrence of acute GVHD. 9 Moreover, the risk of inducing severe acute GVHD appears to be less if the lymphocytes are infused after the primary tissue injury has resolved. 10 Therefore, conditioning related inflammation, as a first crucial step in induction of acute GVHD has to be considered when designing new approaches for aGVHD prevention. We herein report the results of the experimental approaches of delayed BMT after total body irradiation (TBI) or delayed sequential transplantation and the impact of these modalities on development and severity of acute GVHD.
Material and methods
During the study, male 6-10 weeks old animals were used. BalB/C (H-2 d ) mice were used as recipients and C57 bl/6 (H-2 b ) mice as donors. Groups of 8-10 BalB/c mice were placed in a Plexiglas container and given a single dose of TBI of 800 cGy using a linear accelerator source at a dose rate of 3.4 Gy/min.
Bone marrow transplantation
Pooled bone marrow suspensions were prepared in RPMI 1640 from the femurs and tibias of C57Bl/6 mice. The cell suspensions were washed and 1 Â 10 7 bone marrow cells (BMC) were adjusted in 0.1 ml PBS. To enhance the GVH lesions in this model, T cell-enriched splenocytes (SC) from donor mice were added to the bone marrow. To obtain single-cell suspensions, SC were passed several times through 25 gauge needles, washed, and then the desired number of cells was adjusted in 0.2 ml PBS. A total of 0.3 ml containing bone marrow and spleen cells was administered intravenously into recipient animals. Transplantation was carried out as follows: group (1): TBI on day 0 without transplantation (TBI only; n ¼ 5); group (2): TBI on day 0 and transplantation of allogeneic C57 Bl/6 (1 Â 10 7 BMC þ 1 Â 10 7 SC) on day þ 1 (TBI þ day 1 transplantation; n ¼ 10); group (3): TBI on day 0 and transplantation of C57 Bl/6 cells (1 Â 10 7 BMC þ 1 Â 10 7 SC) on day 4 after irradiation (TBI þ day 4 transplantation; n ¼ 10); group (4): TBI on day 0 and transplantation of C57Bl/6 cells (2.5 Â 10 6 BMC þ 2.5 Â 10 6 SC) starting from day 4 through day 8 (TBI þ delayed sequential transplantation; n ¼ 10). Multiple pilot studies preceded this study and the results reported here are derived from three definitive studies.
Follow-up
Groups of five transplanted mice were housed in sterile breeding conditions in an animal house with limited access. Mice were monitored daily for survival and body weight examination was carried out at the time of animal death.
Histological examination
The liver, spleen, skin, and small and large intestines were obtained at the time of animal death or at day þ 60 after transplantation. The tissues were fixed in 10% formalin and embedded in paraffin, sectioned and stained with hematoxylin and eosin.
Detection of engraftment
Surviving mice were killed 2 months after transplantation by cervical dislocation and the spleen cells were harvested. The percentage of donor-derived cells was determined separately for each recipient by flow cytometery (FACScan; Becton Dickinson, CA, USA). The cells were washed twice with saline and then stained with anti-H2 b monoclonal antibody conjugated with phycoerythrin. The cells were washed twice after staining and the two-color fluorescence then was measured.
Statistics
Double-tailed student's t-tests were used for data analysis.
Results

Survival (Figure 1)
All the mice that received TBI only died at days 10 and 11 after total body irradiation ( Figure 1 ). All Balb/c mice treated with TBI and transplanted at day þ 1 with allogeneic C57Bl/6 cells developed acute GVHD and died by day þ 15. In total, 70% of Balb/c mice treated with TBI and transplanted at day 4 were still surviving by day 60 (Po0.001, when compared to day þ 1 transplanted animals). Survival rates were 90% at day 60 for Balb/c mice treated with TBI and their transplantation staggered through day 4 and day 8 (P-value o0.001 when compared to day þ 1 transplanted animals and 0.1 when compared to day þ 4 transplanted animals). Histological examination at the time of animal death confirmed GVHD as the cause of death.
Body weight
Body weight is a sensitive parameter for aGVHD. All mice lost weight in the first week after TBI. The TBI plus day þ 1 allogeneic C57Bl/6 transplanted animals had the greatest weight loss in the first week and continued to lose weight until the time of animal death. The TBI plus day þ 4 allogeneic C57Bl/6 transplanted animals developed weight loss in the first week after TBI. The body weight started to recover in the following weeks to reach the base line by day 40. The delayed sequential transplant only group of mice had the least weight loss in the first week after TBI, began to recover in the second week and completely recovered their weight by day 30.
Engraftment
The transplantation at day 4 after TBI and the sequential transplantation from day 4 to day 8 after TBI was associated with significant engraftment in both groups with no significant differences in the percentages of donor derived cells between both groups (9572.6% (s.e.m.) vs 9373.4%, P40.05) ( Table 1) . Engraftment data for the mice transplanted one day after TBI could not be assessed as all the transplanted animals had died by day þ 15.
Discussion
GVHD has been the primary limitation to the wider application of allogeneic bone marrow transplantation. The pathogenesis of acute GVHD is a multistep process. It Delayed or delayed sequential bone marrow transplantation M Mabed et al occurs in three sequential steps: conditioning regimens, donor T-cell activation and effector mechanisms. The conditioning regimen simultaneously damages and activates host tissues, amplifying antigen presentation to allogeneic donor T cells. [11] [12] [13] [14] [15] TBI and large doses of cyclophosphamide 3, 4 have been shown to induce host inflammatory cytokine release. These cytokines cause or aggravate host tissue damage 16 and modulate MHC antigen expression. 7, 8 Acute GVHD is closely associated with the intensity and toxicity of the conditioning regimens. 17, 18 Donor T cells, activated by host alloantigens, proliferate and secrete a variety of cytokines that are critical for aGVHD. A reciprocal interaction between host products and the transplanted allogeneic effector cells and their products plays a major role in the pathogenesis of lethal acute GVHD. TBI alone increased TNF-a and IL-1a release followed by IL-6 in the absence of allogeneic transplantation. TNF-a, IL-1a and IL-6 levels were significantly augmented and remained high if TBI and H-2 incompatible transplantation were administered together as compared with that when TBI and transplantation were administered separately. 4 This synergistic inflammatory cell cytokine reaction cycle induced by conditioning and allogeneic transplantation may result in further tissue damage and lethal acute GVHD.
Allogeneic transplantation during this sensitive period may further activate effector cells and augment the inflammatory cytokine release. In our study, delaying the inoculation time after TBI conditioning markedly reduced acute GVHD mortality. Similarly, Xun et al 19 have found that delaying transplantation by 4 days after TBI markedly reduced acute GVHD mortality in normal hosts after major histocompatible transplantation. The 4-day rest between TBI and allogeneic transplantation might break the interaction of cell/inflammatory cytokine reactions stimulated by TBI and incompatible transplantation.
In our study, delaying transplantation by 4 days did not adversely affect the engraftment. This finding has been proven in both allogeneic 19 and xenogeneic (human-mouse) models. 20 Similarly, a delay between conditioning and marrow infusion significantly improved allogeneic engraftment in nonmyeloablative conditioned recipients. The highest proportion of recipients engrafted when the marrow was infused on day 4. 21 To enhance the grafting efficiency of bone marrow transplantation, lethally irradiated recipient mice were transplanted with BMC either in one large number or in four separate small numbers. The degree of GVHD in mice which received four separate small numbers was less severe and their survival rates were significantly higher with significant grafting efficiency than the mice which received one large dose of BMC. 22 We have obtained the same results when the transplantation was delayed by 4 days and staggered over another 4 days.
Delaying transplantation as carried out in our study may have the same rational of delaying infusion of immunocompetent cells (DLI) after BMT. When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD was accompanied by persistence of host cells and post transplant relapse. Delayed infusion of immuno-competent donor cells after T cell-deficient BMT eliminated residual host cells and provided an antileukemic effect without causing lethal GVHD. Therefore, post-transplant adoptive immunotherapy with normal mononuclear cells from the marrow donor may be an effective way to eliminate residual disease or treat leukemia relapse after BMT without causing significant GVHD. 10 Multiple infusions of immuno-competent donor cells could be administered without increasing the risk for GVHD if delayed until 21 days post BMT. Delayed infusions of donor spleen cells also resulted in a long-term antileukemic effect in the absence of GVHD. 23 Another strategy for reducing the severity of GVHD after DLI is the selective administration of CD4 or CD8T cell subsets. Delayed infusion of purified T cell subsets 3 weeks post transplant resulted in significantly less GVHD than infusion of a mixture of the two subsets. No GVHassociated mortality was observed after DLI with purified donor CD4 þ T cells. 24 In conclusion, our data demonstrate that either the delay in transplanting alone or delayed sequential allogeneic transplantation after TBI are simple approaches to prevent acute GVHD. The time interval between myeloablative therapy and marrow infusion needs to be optimized to ensure prompt engraftment without subsequent complications. Delayed or delayed sequential bone marrow transplantation M Mabed et al
